PIK3CD and neoplasm: Another study demonstrated that intermittent administration of mitogen-activated protein kinase kinase (MEK) inhibitor, GDC-0973 with a PI3K inhibitor (GDC-0941) triggered cell death and tumor growth inhibition [47].